ORA - Oxford University Research Archive

1 - 8 of 8

1

Conference item

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Nash, P, Coates, LC, Kivitz, AJ, et al.
2018-10-15

2

Conference item

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation

Conference abstract
Taylor, P, Mease, PJ, Bushmakin, AG, et al.
2019-05-27

3

Conference item

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis

conference abstract
Coates, LC, Gottlieb, AB, Shuler, CL, et al.
2016-07-15

4

Conference item

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity

conference abstract
Mease, PJ, Gladman, DD, Collier, D, et al.
2019-05-27

5

Conference item

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

conference abstract
Nash, P, Coates, LC, Kivitz, AJ, et al.
2018-06-12

6

Conference item

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis

conference abstract
Ogdie, A, de Vlam, K, Bushmakin, AG, et al.
2018-10-15

7

Conference item

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib

conference abstract
de Vlam, K, Ogdie, A, Bushmakin, AG, et al.
2018-10-15

8

Conference item

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease

Cappelleri, JC, Bushmakin, AG, De Vlam, K, et al.
2020-06-02

TO TOP